Autologous peripheral blood stem cell transplantation for lung cancer.

Lung carcinoma, the most frequent cause of cancer-related death in both men and women, remains a difficult therapeutic problem. Small-cell lung carcinoma, despite its high response rate to chemotherapy, is associated with a rapid recurrence and ultimately limited overall survival. In attempts to exploit tumour chemosensitivity, high-dose chemotherapy (HDC) combining several active drugs has been studied to improve outcome. In addition, haematopoietic stem cell support has been used to allow dose escalation without major myelosuppression. In contrast to small-cell carcinoma, non-small-cell carcinoma of the lung is generally not very responsive to chemotherapy, and results with dose intensity in unresectable tumour have so far been very disappointing. We review the results of HDC in terms of response and survival, and discuss potential strategies to improve the effectiveness of dose intensity.

[1]  P. Woll,et al.  Dose intensity in small cell lung cancer. , 1998, Seminars in oncology.

[2]  G. Pelosi,et al.  Positive immunostaining with MLuC1 of bone marrow aspirate predicts poor outcome in patients with small-cell lung cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Verweij,et al.  Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Machiels,et al.  Retroviral-mediated gene transfer of human multidrug resistance associated murine hematopoietic cells , 1998 .

[5]  V. D’Hondt,et al.  Retrovirus-mediated gene transfer of the multidrug resistance-associated protein (MRP) cDNA protects cells from chemotherapeutic agents. , 1997, Human gene therapy.

[6]  R. Ward,et al.  Unconjugated antibodies for cancer therapy: lessons from the clinic. , 1997, Cancer treatment reviews.

[7]  G. Giaccone,et al.  Detection of cytokeratin-19 transcripts by reverse transcriptase-polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[8]  R. Livingston,et al.  14 A randomized study of CODE plus thoracic irradiation versus alternating CAVEP for extensive stage small cell lung cancer (ESCLC): An intergroup study of the national cancer institute of Canada and the southwest oncology group , 1997 .

[9]  L. Kanz,et al.  Early high-dose chemotherapy and peripheral blood progenitor cell transplantation in limited-disease small-cell lung cancer. Results of a single center phase II study , 1997 .

[10]  D. Williams,et al.  Establishing chemoresistance in hematopoietic progenitor cells. , 1997, Molecular medicine today.

[11]  K. Pantel,et al.  Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Mulshine,et al.  Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. , 1997, Chest.

[13]  D. Esseltine,et al.  Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Kanz,et al.  Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Marangolo,et al.  Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: an EBMT study. , 1996, Bone marrow transplantation.

[16]  Y. Humblet,et al.  High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells. , 1996, Bone marrow transplantation.

[17]  K. Pantel,et al.  Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases , 1996, The Lancet.

[18]  P. Woll,et al.  Randomised phase II study of standard versus dose-intensive ICE chemotherapy with reinfusion of haemopoietic progenitors in whole blood in small cell lung cancer (SCLC). , 1996 .

[19]  K. Müller,et al.  Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Clive R. Taylor,et al.  Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. , 1995 .

[21]  K. Kelly,et al.  A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study. , 1995, Seminars in oncology.

[22]  T. Dexter,et al.  Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Pelosi,et al.  Detection at diagnosis of tumor cells in bone marrow aspirates of patients with small-cell lung cancer (SCLC) and clinical correlations. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  T. le Chevalier,et al.  Chemotherapy of stage IIIB and IV non-small-cell lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  R. Souhami,et al.  Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Palackdharry Cs,et al.  Dose-intensive ifosfamide/carboplatin/etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer. , 1994 .

[27]  W. Gilks,et al.  Antigens of lung cancer: results of the Third International Workshop on Lung Tumor and Differentiation Antigens. , 1994, Journal of the National Cancer Institute.

[28]  R. Feld.  High-dose or dose-intensive chemotherapy for non-small cell carcinoma of the lung. , 1994, Seminars in oncology.

[29]  J P Pignon,et al.  Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. , 1993, The New England journal of medicine.

[30]  M. Paesmans,et al.  Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Izbicki,et al.  Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.

[32]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[33]  D. Rubinstein,et al.  Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines. , 1993, Cancer research.

[34]  J. Crowley,et al.  Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Eder,et al.  Intensive combined modality therapy for limited-stage small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[36]  J. Crown,et al.  Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. , 1992, Journal of the National Cancer Institute.

[37]  D. Ihde,et al.  Chemotherapy of Lung Cancer , 1992 .

[38]  S. Aamdal,et al.  Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods. , 1992, The American journal of pathology.

[39]  A. Coldman,et al.  Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Thatcher,et al.  High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study. , 1991, British Journal of Cancer.

[41]  R. Leonard,et al.  Immunocytological detection of residual marrow disease at clinical remission predicts metastatic relapse in small cell lung cancer. , 1990, Cancer research.

[42]  T. Spitzer,et al.  Phase I Trial of High‐Dose Etoposide, High‐Dose Cisplatin, and Reinfusion of Autologous Bone Marrow for Lung Cancer , 1990, American journal of clinical oncology.

[43]  R. Souhami,et al.  Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. , 1990, British Journal of Cancer.

[44]  J. Estève,et al.  Cancer in the European Community and its member states. , 1990, European journal of cancer.

[45]  V. Combaret,et al.  Bone marrow metastases in small cell lung cancer: detection with magnetic resonance imaging and monoclonal antibodies. , 1989, British Journal of Cancer.

[46]  H. Golomb,et al.  High‐dose, multiple‐alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non‐small cell lung cancer , 1989, Cancer.

[47]  C. Wilson,et al.  High dose chemotherapy with autologous bone marrow rescue in small cell lung cancer. , 1988, In vivo.

[48]  L. de Leij,et al.  Detection of small cell lung cancer metastases in bone marrow aspirates using monoclonal antibody directed against neuroendocrine differentiation antigen. , 1988, Journal of clinical pathology.

[49]  J. Minna,et al.  Monoclonal antibodies for the in vitro detection of small cell lung cancer metastases in human bone marrow. , 1988, European journal of cancer & clinical oncology.

[50]  Y. Humblet,et al.  Immunodetection of small cell lung cancer metastases in bone marrow using three monoclonal antibodies. , 1988, European journal of cancer & clinical oncology.

[51]  A. Ford,et al.  Clinical applications of immunocytochemistry in the monitoring of the bone marrow in small cell lung cancer (SCLC) , 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[52]  Y. Humblet,et al.  Detection of small cell lung cancer bone marrow metastases by tumor stem cell assay. , 1988, Pathologie-biologie.

[53]  J. Machiels,et al.  Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  R. Abrams,et al.  Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  A. Zander,et al.  High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Stahel,et al.  Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  J. Sculier,et al.  Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  F. Appelbaum,et al.  Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung. , 1983, Cancer treatment reports.

[59]  J. Minna,et al.  Intensive chemotherapy of small cell bronchogenic carcinoma. , 1977, Cancer treatment reports.